62.32 USD
+0.84
1.37%
At close Mar 27, 4:00 PM EDT
After hours
62.32
+0.00
0.00%
1 day
1.37%
5 days
2.20%
1 month
-1.41%
3 months
-14.16%
6 months
-22.89%
Year to date
-13.13%
1 year
-19.43%
5 years
87.37%
10 years
91.81%
 

About: Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.

Employees: 7,063

0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 7 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

9% more call options, than puts

Call options by funds: $39.4M | Put options by funds: $36.2M

2% more first-time investments, than exits

New positions opened: 87 | Existing positions closed: 85

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

0.34% less ownership

Funds ownership: 97.79% [Q3] → 97.45% (-0.34%) [Q4]

2% less funds holding

Funds holding: 712 [Q3] → 700 (-12) [Q4]

12% less capital invested

Capital invested by funds: $18.5B [Q3] → $16.3B (-$2.19B) [Q4]

13% less repeat investments, than reductions

Existing positions increased: 247 | Existing positions reduced: 285

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$70
12%
upside
Avg. target
$80
28%
upside
High target
$90
44%
upside

7 analyst ratings

positive
29%
neutral
71%
negative
0%
Citigroup
Patrick Donnelly
26% 1-year accuracy
8 / 31 met price target
12%upside
$70
Neutral
Maintained
4 Mar 2025
Raymond James
Andrew Cooper
13% 1-year accuracy
2 / 15 met price target
44%upside
$90
Outperform
Reiterated
6 Feb 2025
RBC Capital
Conor McNamara
8% 1-year accuracy
3 / 37 met price target
36%upside
$85
Sector Perform
Maintained
6 Feb 2025
Evercore ISI Group
Vijay Kumar
38% 1-year accuracy
18 / 47 met price target
17%upside
$73
In-Line
Maintained
6 Feb 2025
Stephens & Co.
Mason Carrico
32% 1-year accuracy
9 / 28 met price target
35%upside
$84
Overweight
Reiterated
6 Feb 2025

Financial journalist opinion

Based on 9 articles about HOLX published over the past 30 days

Negative
Investors Business Daily
6 hours ago
How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply Chain
Tariff uncertainty has cast a pall over medical stocks. Re-shoring is possible, but expensive, leaving them in a "wait-and-see" pattern.
How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply Chain
Negative
Zacks Investment Research
2 days ago
Hologic (HOLX) Advances But Underperforms Market: Key Facts
In the most recent trading session, Hologic (HOLX) closed at $61.89, indicating a +0.68% shift from the previous trading day.
Hologic (HOLX) Advances But Underperforms Market: Key Facts
Positive
Zacks Investment Research
1 week ago
New Product Launches to Support HOLX Stock Amid Macro Issues
Hologic's Surgical business has been driving strong broad-based performance by expanding access to technologies in new global markets.
New Product Launches to Support HOLX Stock Amid Macro Issues
Positive
Zacks Investment Research
1 week ago
HOLX Stock Down 24.7% in 6 Months: Time to Cut Losses or Buy the Dip?
As Hologic works through the changing macroeconomic and geopolitical landscape, its long-term potential makes it a solid hold.
HOLX Stock Down 24.7% in 6 Months: Time to Cut Losses or Buy the Dip?
Positive
Zacks Investment Research
1 week ago
Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know
Negative
Zacks Investment Research
2 weeks ago
Why Is Hologic (HOLX) Down 4.5% Since Last Earnings Report?
Hologic (HOLX) reported earnings 30 days ago. What's next for the stock?
Why Is Hologic (HOLX) Down 4.5% Since Last Earnings Report?
Positive
Zacks Investment Research
2 weeks ago
Here is What to Know Beyond Why Hologic, Inc. (HOLX) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
Here is What to Know Beyond Why Hologic, Inc. (HOLX) is a Trending Stock
Negative
Zacks Investment Research
4 weeks ago
Hologic Wins Key Approvals Post Q1 Results: Buy or Hold HOLX Stock?
HOLX's latest regulatory successes draw investors' attention. However, macroeconomic challenges restrict its full growth potential.
Hologic Wins Key Approvals Post Q1 Results: Buy or Hold HOLX Stock?
Neutral
Business Wire
4 weeks ago
Hologic to Webcast Presentation at the Raymond James 46th Annual Institutional Investors Conference
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #holx--Hologic to Webcast Presentation at the Raymond James 46th Annual Institutional Investors Conference.
Hologic to Webcast Presentation at the Raymond James 46th Annual Institutional Investors Conference
Positive
Zacks Investment Research
1 month ago
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Hologic (HOLX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know
Charts implemented using Lightweight Charts™